Detail

Gadobenate Dimeglumine

Description

Name: Gadobenate Dimeglumine
Type: small molecule
Groups: approved
Indication: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
Accession Number: DB00743 ( APRD00989)
Description: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Multihanceinjection, solution529 mg/mLintravenous23-11-2004US
Multihanceinjection, solution529 mg/mLintravenous23-11-2004US
Multihancesolution529 mgintravenous28-10-2004Canada

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
MultihanceGadobenate Dimeglumine
MultihanceGadobenate Dimeglumine
MultihanceGadobenate Dimeglumine

Categories
  • Contrast Media

Pharmacology

Indication: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Plasma protein binding is low, weak, and transient.
Metabolism: Not Available
Route of elimination: Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.
Half life: 1 hour
Clearance: Not Available
Toxicity: Gadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Bracco diagnostics inc

Packagers:
Dosage forms
FormRouteStrength
Injection, solutionintravenous529 mg/mL
Solutionintravenous529 mg

Prices
Unit descriptionCostUnit
Multihance 529 mg/ml vial$6.87ml

Patents
CountryPatent NumberApprovedExpires (estimated)
4916246United States1995-04-102012-04-10

Interactions

Drug Interactions
DrugInteraction
CitalopramGadobenate Dimeglumine may increase the QTc-prolonging activities of Citalopram.
DofetilideGadobenate Dimeglumine may increase the QTc-prolonging activities of Dofetilide.
GoserelinGoserelin may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
IvabradineIvabradine may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
OctreotideOctreotide may increase the QTc-prolonging activities of Gadobenate Dimeglumine.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Not Available
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Not Available

substituent:
  • Not Available

References

Synthesis Reference: Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato, "Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form." U.S. Patent US20120232151, issued September 13, 2012.
General Reference: # de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608412 # Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17921081 # Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1546612 # Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9818314 # Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608397
External Links:
ResourceLink

ATC Codes:
  • Array

AHFS Codes:
  • 92:00.00

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?